@FierceMedDev: InVivo slides again as CFO bolts, spinal study pends. ICYMI yesterday | Follow @FierceMedDev
@DamianFierce: Covidien projects a modest 2014, its first full year with no pharma revenue. Report | Follow @DamianFierce
@MarkHFierce: We have a new round of stories at FierceDiagnostics. Check them out | Follow @MarkHFierce
@MichaelGFierce: This week, in life sciences hiring: Ex-Bausch + Lomb CEO takes helm at Forest Labs... and more. Chutes & Ladders | Follow @MichaelGFierce
> Smith & Nephew ($SNN) has rolled out a new antimicrobial wound dressing in the U.S., made with silver. Item
> Abbott ($ABT) will be issuing its 359th consecutive quarterly dividend, this time at 14 cents per share. Item
> Tyber Medical nailed down a CE mark for its new interbody fusion device. Item
> Cyberonics ($CYBX) has brought on a former St. Jude Medical ($STJ) executive as its new senior vice president of strategic planning. Story
> Emergent Medical Partners has raised $37 million for a fund that will focus on early-stage med tech investing. Item
> DFine gained a CE mark for its Star tumor ablation system that treats metastatic spinal tumors. Item
Biotech News
@FierceBiotech: Trending now: Biotech R&D spending roars ahead as Big Pharma grimly holds the line. ICYMI yesterday | Follow @FierceBiotech
@JohnCFierce: Delcath gets a CRL, a demand for a new trial, some other hurdles, and fires its CEO. Busy day. Release | Follow @JohnCFierce
@EmilyMFierce: NIH partners with Eli Lilly, others on rare diseases. Article | Follow @EmilyMFierce
> Party drug ketamine gains steam for antidepressant use. Item
> Egalet scores up to $20M for next-gen pain drug as FDA aims to block abuse. Story
> Delcath gets FDA denial on cancer treatment and axes CEO. Article
> Visterra's engineered antibody passes preclinical test as universal flu treatment. More
Pharma News
@FiercePharma: Ruling against GSK's Lovaza fish-oil pill puts hurt on competitor Amarin. Story | Follow @FiercePharma
@EricPFierce: South Africa's Aspen says manufacturing assets it is getting from GSK, Merck part of global push. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI: Is J&J's manufacturing any better off since it pledged to keep closer oversight? Second recall in two weeks. Report | Follow @CarlyHFierce
> Lilly files $500M lawsuit against Canada. News
> Germany's Bayer joins crowd of companies under Chinese investigation. More
> J&J trying to drag Boehringer into arbitration over Doxil production lapses. Article
> FDA panel gives 'historic' thumbs-up to Roche's Perjeta in early breast cancer. News